论文部分内容阅读
肺癌中约80%为非小细胞肺癌(NSCLC),其中约70%就诊时就无法手术,约50%在术后复发或转移,晚期的NSCLC 中位生存期不超过32周,NVB(navelbine)是一种新型半合成的长春碱类抗癌药,该药对非小细胞肺癌疗效显著,我们从1996年1月到1999年6月应用 NVB 联合 DDP治疗晚期 NSCLC 23例,取得了较好的疗效,现报告如下:1 材料与方法1.1 临床资料全组共23例,男性15例,女性8例,中位年龄52岁。23例患者中,腺癌13例,鳞癌8例,大细胞肺癌2例;初治15
About 80% of lung cancers are non-small cell lung cancer (NSCLC), of which approximately 70% are inoperable at surgery, approximately 50% are postoperative recurrences or metastases, and late median survival for NSCLC is no more than 32 weeks. NVB (navelbine) Is a new type of semi-synthetic vinblastine anticancer drug, the drug has a significant effect on non-small cell lung cancer, we applied NVB combined with DDP in 23 cases of advanced NSCLC from January 1996 to June 1999, and achieved better The curative effect is as follows: 1 Materials and methods 1.1 The clinical data of the entire group consisted of 23 patients, including 15 males and 8 females, with a median age of 52 years. Among 23 patients, there were 13 adenocarcinomas, 8 squamous cell carcinomas, and 2 large cell lung cancers;